Business Update & Financial Outlook

Oncology: Solid performance across broad portfolio Lynparza • Lynparza¹ sales grew 15% driven primarily by increased demand in certain international markets Lenvima² sales grew 6% due to demand in advanced RCC and endometrial cancer in the U.S., partially offset by lower sales in China $248M +34% Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai olaparib tablets 150 mg $310M $275M +15% +17% 2Q21 2Q22 2Q23 LENVIMA (lenvatinib) capsules 10mg and 4 g mg $181M +15% $231M +33% $242M +6% 2Q21 2Q22 2Q23 MERCK 12

View entire presentation